TANGO THERAPEUTICS, INC. (TNGX) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - TANGO THERAPEUTICS INC

Explicit Guidance:

• None provided. Management explicitly declined to discuss specific financial metrics (revenue, earnings, capex) or statistical analysis plans, citing FDA confidentiality preferences.

Business-Segment Outlook:

• Pancreatic Cancer (PDAC): Initiation of a Phase 3, first-line study (240 patients per arm) scheduled for the first half of 2025. The study will compare Vopimedastat + Daroxasib-Rasip or Zoldan-Rasip against investigator-choice chemotherapy, using Response Rate (RR) and Progression-Free Survival (PFS) as dual primary endpoints.
• Second-Line PDAC: A Phase 2 study is currently open for enrollment; management intends to discuss an accelerated approval strategy with the FDA before the end of the current year.
• Non-Small Cell Lung Cancer (NSCLC): Plans to share development strategy and patient selection data for the blood-brain barrier-penetrating candidate TNG456 in January 2027.
• Glioblastoma (GBM): Current study in relapsed/refractory patients; strategy for the adjuvant setting will be evaluated and potentially announced in January 2027, contingent on data attractiveness.
• Product Positioning: Potential dichotomy established where Vopimedastat targets pancreatic cancer (non-CNS) and TNG456 targets NSCLC (CNS involvement).

Market and Competitive Outlook:

• Differentiation Strategy: Management asserts Tango holds the "best PMT-5 inhibitor" and anticipates the market differentiator will be safety, tolerability, and combinability rather than pure efficacy.
• Competitive Landscape: Anticipates that while other companies are developing similar PureMT5 inhibitor combinations, Tango's superior safety profile (specifically lack of Grade 3 rash/stomatitis in the Vopimedastat combo) will drive preference.
• Market Timing: Management believes they will be the first to bring the optimal PMT-5 inhibitor combination to market.

Macro / Industry Outlook:

• Regulatory Environment: Describes a "very, very good relationship" with the FDA regarding the safety profile of Vopimedastat. The FDA was "very supportive" and "comfortable" with the Phase 3 design and statistical plan.
• Approval Pathways: Dual primary endpoints (RR and PFS) provide flexibility for potential early submission and accelerated approval discussions.

Strategic Initiatives:

• Supply Chain: Currently negotiating an extension of the supply agreement with Revolution Medicines for Phase 3 materials. Management has confirmed the study will proceed without delay even if an agreement is not finalized, prioritizing speed over partnership continuity.
• Collaborations: Advanced the first-in-human study of Eraska-0015 in combination with Vopimedastat; finalizing a comprehensive development plan with Arasca (Eraska).
• Organizational Transformation: Transitioned from a discovery-stage entity to a late-stage, pre-commercial organization with laser-sharp execution focus.

Risks and Headwinds to Outlook:

• Supply Agreement: Risk of delay or lack of cooperation from Revolution Medicines in finalizing supply terms for the Phase 3 study.
• Second-Line Strategy: Uncertainty remains regarding FDA requirements for demonstrating the "contribution of components" for accelerated approval in the second-line setting.
• Data Milestones: Advancement into NSCLC or GBM is contingent on receiving compelling data in the upcoming January 2027 updates.
• Clinical Execution: The study startup is currently dependent on operational readiness (site selection, CRO engagement).

Management Tone on the Future:

• Confidence Level: High. Management expresses being "extremely happy," "confident," and "very strongly" supportive of the data, noting the transition from a discovery org to a late-stage org has been successful.
• Speed: Emphasizes that "speed" is the key component; they are prepared to execute studies independently if partnership negotiations stall.
• Validation: Views the clinical confirmation of preclinical synergy as a major validation of their R&D hypothesis.

Miscellaneous:

• Dose Management: Drug-drug interactions are managed by lowering the Vopimedastat dose to automatically reduce exposure to the partner agents (Daroxasib/Zoldan + Rasip), mitigating toxicity risks.
• KRAS G12D: While early data is pending, management is "very confident" the combination will show high synergy in G12D patients, supported by high efficacy in the difficult-to-treat G12R cohort.